Copaxone Articles

Net Profits Up 11% For Teva In 1995

11 March 1996

Teva's Copaxone In USA

11 March 1996

Israel's Teva Bidding For World Generics Leadership

12 February 1996

Teva / Hoechst Marion Roussel Copaxone collab

15 January 1996

Biogen's Interferon Beta Nears US Approval

4 December 1995

Improved Third Quarter For Teva Pharmaceutical

20 November 1995

Teva: Copaxone trials news

13 November 1995

Teva Makes $26M Bid For Majority Stake In Biogal

13 November 1995

MS: Hope, Expectations, And Disappointments

23 October 1995

More Israeli Court Action Over MS Drug

11 September 1995

Teva's Copaxone Disappointment

4 September 1995

Disappointing Second Quarter From Teva

14 August 1995

Teva Pharmaceutical: Copaxone

26 June 1995

Israeli GSF "Must Supply Betaseron To MS Patient"

5 June 1995

Biogen Files For Avonex MS Drug In USA

29 May 1995

Biogen Files For Avonex MS Drug In USA

29 May 1995

FDA: Problems With Accepting EMEA Data

22 May 1995

MMD/Teva Agreement

20 March 1995

Teva Moves To Cope With Increased Competition

20 March 1995

MMD To Market Teva's Copaxone

6 February 1995

Teva Copaxon Unit

30 January 1995

...And Israel's Teva Recommended

2 January 1995

World Immunology, Rheumatology Markets

28 November 1994

Teva Pharma's Net Income Up 25% For 3rd Qtr

28 November 1994

Phase III Results For Copolymer 1 Disappointing

17 October 1994

Teva To File COP-1 NDA In Late 1994/Early 1995

1 August 1994

Teva profit falls 57% on acquisition charges